TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Portnoy Law Firm
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors

Skye Bioscience investors are being advised of a class action lawsuit covering the period from November 4, 2024 to October 3, 2025. The action follows Skye's October 6, 2025 announcement that its nimacimab drug failed to achieve the primary endpoint of weight loss compared to placebo in a Phase 2a study, with lower than expected drug exposure. The stock price fell 60% to $1.90 per share on the news.

Insights
SKYE   negative

The company's lead drug candidate failed to meet primary endpoints in clinical trials, resulting in a 60% stock price decline. The failure to achieve weight loss compared to placebo and lower than expected drug exposure indicate significant setbacks for the company's pipeline and investor value.